|Application No.||Application Title||Issue Date|
|20140051680||Histone Deacetylase Inhibitors|
This invention relates to generally inhibiting histone deacetylase (HDAC) enzymes (e.g., HDAC1, HDAC2, and HDAC3)....
|20140051729||COMPOSITIONS AND METHODS FOR TREATING DEGENERATIVE MUSCLE CONDITIONS|
Methods and compositions for treating degenerative muscle conditions are disclosed. The compositions disclosed herein include S1P promoting compositions that include an S1P promoting agent. Embodiments of the methods disclosed herein include administering therapeuticall...
|20140051689||Polycyclic Agents for the Treatment of Respiratory Syncytial Virus Infections|
Compounds of formula (I), and their use as in the treatment of infections involving viruses of the Pneumovirinae sub-family (RSV) are disclosed. In the formula ring (A) may be phenyl, pyridyl etc., (B-C) may be CH2—CH2 etc., (R1) may b...
|20140045795||COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS|
The invention relates to compounds of structural formula (I):
|20140024530||USE OF N-(TETRAZOL-4-YL)- OR N-(TRIAZOL-3-YL)ARYLCARBOXAMIDES OR THEIR SALTS FOR CONTROLLING UNWANTED PLANTS IN AREAS OF TRANSGENIC CROP PLANTS BEING TOLERANT TO HPPD INHIBITOR HERBICIDES|
Use of N-(tetrazol-4-yl)- or N-(triazol-3-yl)arylcarboxamides of formula (I) or salts thereof
for controlling unwanted plants in areas of transgenic crop plants being tolerant to HPPD inhibitor herbicides by ...
|20140018377||Aminopropenoates as Fungicides|
This application claims priority to European Patent Application No. 09173304.8, filed Oct. 16, 2009, and the benefit of U.S. Provisional Application No. 61/253,091, filed Oct. 20, 2009, the disclosure of each of which is incorporated by reference herein in its entirety....
Provided are novel compounds that bind to FKBP12 or pharmaceutically acceptable salts thereof, as well as new therapeutics useful in the prevention or treatment of alopecia which comprise those compounds or pharmaceutically acceptable salts thereof. Specifically, compou...
|20130345222||IDENTIFICATION OF HUMAN T2R RECEPTORS THAT RESPOND TO BITTER COMPOUNDS THAT ELICIT THE BITTER TASTE IN COMPOSITIONS, AND THE USE THEREOF IN ASSAYS TO IDENTIFY COMPOUNDS THAT INHIBIT (BLOCK) BITTER TASTE IN COMPOSITIONS AND USE THEREOF|
The present invention relates to the discovery that specific human taste receptors in the T2R taste receptor family respond to particular bitter compounds present in, e.g., coffee. Also, the invention relates to the discovery of specific compounds and compositions conta...
Compounds of the formula I Formula (I) wherein the substituents are as defined in claim 1, are useful as active ingredients, which have microbiocidal activity, in particular fungicidal activity.
|20130317007||ANTIOXIDANT INFLAMMATION MODULATORS: OLEANOLIC ACID DERIVATIVES WITH AMINO AND OTHER MODIFICATIONS AT C-17|
This invention provides, but is not limited to, novel oleanolic acid derivatives having the formula:
wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles ...
|20130296310||THIAZOLE AND OXAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS|
Compounds of the formula I:
or a pharmaceutically acceptable salt thereof, wherein, R1 is a group of formula A or formula B,
and X, R
|20130289026||Isoxazole Compounds As Inhibitors Of Heat Shock Proteins|
Isoxazoles of formula (A) or (B) are inhibitors of HSP90 activity, and useful for treatment of, for example cancers:
wherein R1, is a group of formula (IA): —Ar1-(Alk1)...
The present invention provides novel radioiodinated guanidines. Also provided are methods of preparation of said radioiodinated guanidines from non-radioactive precursors, as well as radiopharmaceutical compositions comprising such radioiodinated guanidines. The inventi...
|20130274212||Sesterterpene Compounds and Use Thereof|
The present invention relates to sesterterpene compounds, to the precursors thereof that are hydrolysable in a living body, or to the pharmaceutically acceptable salts thereof, and also relates to the prevention and treatment efficacy of the sesterterpene compounds with...
|20130272960||RADIOIODINATED FATTY ACIDS|
The present invention provides novel radioiodinated fatty acids. Also provided are methods of preparation of said radioiodinated fatty acids from non-radioactive precursors, as well as radiopharmaceutical compositions comprising such radioiodinated fatty acids. The inve...
|20130267501||Modulators of Aldehyde Dehydrogenase and Methods of Use Thereof|
The present disclosure provides compounds that function as modulators of aldehyde dehydrogenase (ALDH) enzymatic activity, as well as compositions and formulations comprising the compounds. The present disclosure provides therapeutic methods involving administering a su...
|20130237571||AGONISTS OF GPR40|
The present invention relates to compounds that have the ability to modulate the activity of GPR40 and are therefore useful in the treatment of GPR40 related disorders. In addition the invention relates to the compounds, methods for their preparation, pharmaceutical com...
|20130231489||NOVEL ORGANOMETALLIC COMPLEXES WHICH EMIT IN THE RED TO GREEN SPECTRAL REGION AND THEIR USE IN OLEDS|
Organometallic complexes which bear at least one ligand which has a unit having a triplet energy of at least 22 000 cm−1, a process for preparing the organometallic complexes, a mixture comprising at least one inventive organometallic complex, the use of th...
|20130203593||PESTICIDAL COMPOSITIONS AND PROCESSES RELATED THERETO|
This document discloses molecules having the following formulas (“Formula One” & “Formula Two” and “Formula Three”)
The Ar1, Het, Ar2, R1, R2, R3, R4, and R5 are further ...
|20130203592||PESTICIDAL COMPOSITIONS AND PROCESSES RELATED THERETO|
This document discloses molecules having the following formulas (“Formula One” &“Formula Two” and “Formula Three”)
|20130197011||Phenyl-3-aza-bicyclo[3.1.0]hex-3-yl-methanones and the use thereof as medicament|
Substituted phenyl-3-aza-bicyclo[3.1.0]hex-3-yl-methanones which are glycine transporter-1 (GlyT1) inhibitors. These are useful for the treatment of schizophrenia, Alzheimer's Disease and other neurological and psychiatric disorders....
|20130184279||N-((3-BENZYL)-2,2-(BIS-PHENYL)-PROPAN-1-AMINE DERIVATIVES AS CETP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROSIS AND CARDIOVASCULAR DISEASES|
Compounds of formula Ia and Ib
wherein A, B, C, R1 and R14 are described herein....
A compound of formula (I), wherein A is S, O or a double bond, and L is a substituted thiazolyl, phenyl or pyridyl. The compound is useful for the treatment of inflammation and cancer....
A compound of formula (I):
wherein A1, A2, A3, A4, G1, G2, R1, R2, R3 and R4 are as defined in cla...
|20130143880||POSITIVE ALLOSTERIC MODULATORS OF MGLUR2|
The present invention is directed to benzimidazolone derivatives which are positive allosteric modulators of the mGluR2 receptor, useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and disease...
A compound represented by formula [I] and a pharmaceutically accepted salt of said compound are a novel compound and a pharmaceutically accepted salt thereof which exert antagonistic activity against group II metabotropic glutamate (mGlu) receptors, and are effective as...
|20130123243||DIAMINE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE|
This invention is directed to compounds of formula (I):
where r, q, R, R2, R3, R4, R5a, R5b, R5c, R6a, R6b, R6c
|20130109856||NOVEL PROCESS FOR THE PREPARATION OF ACYLGUANIDINES AND ACYLTHIOUREAS|
The present invention relates to a novel process for the preparation of compounds of general formula (I)
and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or orga...
|20130072490||POLYCYCLIC COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS|
Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in combination with o...
|20130072677||NOVEL HYDROXAMIC ACID DERIVATIVE|
Provided is a novel compound which is useful as a pharmaceutical composition by inhibiting an LpxC activity, thereby exhibiting potent antimicrobial activity against gram-negative bacteria including Pseudomonas aeruginosa and its drug resistant bacteria. Provided...
|20130065897||COMPOUNDS, PREPARATION AND USES THEREOF|
The present invention provides novel compounds of the Formula I, pharmaceutical compositions comprising such compounds and methods for using such compounds as agents or drugs for inhibiting perforin activity and for treating a subject at risk of or susceptible to a dise...
|20130065902||3-(HETEROARYL-AMINO)-1,2,3,4-TETRAHYDRO-9H-CARBAZOLE DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS|
The present invention relates to 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9H-carbazole derivatives of the formula (I),
wherein R1, R2 and R3 are as described in the description...
|20130035346||AMIDE DERIVATIVES BEARING A CYCLOPROPYLAMINOACARBONYL SUBSTITUENT USEFUL AS CYTOKINE INHIBITORS|
The invention concerns a compound of the Formula (I), wherein Qa is heteroaryl and is substituted with halogeno; R1 and R2 are hydrogen; and Qb is phenyl or heteroaryl, and Qb may optionally bear 1 or 2 substituents selected from hydroxy, halogeno and (1-6C)alkyl, or a ...
|20130011361||PYRAZOLE DERIVATIVES WHICH MODULATE STEAROYL-COA DESATURASE|
The present invention provides heterocyclic derivatives of formula (I) that modulate the activity of stearoyl-CoA desaturase. Methods of using such derivatives to modulate the activity of stearoyl-CoA desaturase and pharmaceutical compositions comprising such derivative...
|20120322837||AMIDE COMPOUND AND MEDICINAL USE THEREOF|
A compound of formula [I-W]:
wherein each symbol is as defined in the description, or a pharmaceutically acceptable salt thereof....
|20120316173||COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR|
Compounds of formula (I) are disclosed. Compounds according to the invention bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating ...
To provide a novel compound or an isotope thereof or a pharmaceutically acceptable salt thereof having S1P lyase inhibitory capacity and inducing the decrease in number of lymphocytes, and a pharmaceutical composition containing these as active ingredients. A compound r...
In one aspect, the invention relates to compounds having the formula:
where R1, R2, R3, R4, and R5 are as defined in the specification, or a pharmaceutic...
|20120309674||PSEUDODIPEPTIDES AS MMP INHIBITORS|
The invention relates to compounds, in particular MMP inhibitors. The compounds of the invention have formula (1). The invention can be used in particular in the pharmaceutical field. The present invention also relates to labeled compounds of formula (2), and to the use...
|20120309750||5-MEMBERED HETEROCYCLE DERIVATIVES AND MANUFACTURING PROCESS THEREOF|
Disclosed are a novel 5-membered heterocycle derivatives of Formula I, a tautomer, pharmaceutically acceptable salt, prodrug thereof and a pharmaceutical use thereof. The 5-membered heterocycle derivatives of Formula I, a tautomer, pharmaceutically acceptable salt, prod...